Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

662 trials with published results (27%)

Research Maturity

1610 completed trials (65% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

8.3%

206 terminated out of 2489 trials

Success Rate

88.7%

+2.2% vs benchmark

Late-Stage Pipeline

24%

587 trials in Phase 3/4

Results Transparency

41%

662 of 1610 completed with results

Key Signals

662 with results89% success206 terminated

Data Visualizations

Phase Distribution

1,713Total
Not Applicable (460)
Early P 1 (11)
P 1 (280)
P 2 (375)
P 3 (330)
P 4 (257)

Trial Status

Completed1,610
Unknown348
Terminated206
Recruiting138
Active Not Recruiting72
Withdrawn50

Trial Success Rate

88.7%

Benchmark: 86.5%

Based on 1610 completed trials

Clinical Trials (2489)

Showing 20 of 20 trials
NCT05762185Not ApplicableCompleted

Interest of a Nursing Consultation in the Empowerment of the Patient With Rheumatoid Arthritis in the Management of His Subcutaneous Biotherapy

NCT06714461CompletedPrimary

A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia

NCT06565273Phase 2Active Not RecruitingPrimary

Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis

NCT03816345Phase 1Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT00055055CompletedPrimary

Study of Families With Twins or Siblings Discordant for Rheumatic Disorders

NCT07315503Early Phase 1WithdrawnPrimary

An Open-label Study of GC012F in Rheumatoid Arthritis.

NCT07639177Phase 2Not Yet RecruitingPrimary

Faecal Microbiota Transplantation in Patients With Refractory Rheumatoid Arthritis

NCT07607964Phase 1Recruiting

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT05002959Terminated

TESS V3 Modular Total Shoulder System PMCF

NCT07363590Phase 1Recruiting

A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

NCT06972446Phase 2RecruitingPrimary

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

NCT06902519Phase 1RecruitingPrimary

Study of GS-0151 in Participants With Rheumatoid Arthritis

NCT03270982Active Not Recruiting

Comprehensive Segmental Revision System

NCT01700543Completed

Sidus(TM) Post Market Clinical Follow-up (PMCF) Study

NCT02281747Active Not RecruitingPrimary

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries

NCT07632872Phase 2Recruiting

Desloratadine as Adjunct Therapy for Rheumatoid Arthritis

NCT07632846Phase 2RecruitingPrimary

Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis

NCT07171983Phase 1RecruitingPrimary

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis

NCT06293365Phase 2Active Not Recruiting

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06631638Not ApplicableRecruiting

EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))

Scroll to load more

Research Network

Activity Timeline